Latest news with #Wintergreen
Miami Herald
7 days ago
- Business
- Miami Herald
D. Boral Capital Acted as Sole Bookrunner to Wintergreen Acquisition Corp. (Nasdaq: WTGUU) in Connection with its $56.0 Million Initial Public Offering
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / On May 30, 2025, Wintergreen Acquisition Corp. (NASDAQ:WTGUU) ("Wintergreen" or the "Company") announced the closing of its initial public offering of 5,595,000 units. This includes 595,000 units issued pursuant to the underwriter's partial exercise of its over-allotment option, which also closed today, May 30, 2025. The offering was priced at $10.00 per unit, resulting in gross proceeds of $55,950,000. Wintergreen's units are listed on the Nasdaq Capital Market ("NASDAQ") and began trading under the ticker symbol "WTGUU" on May 29, 2025. Each unit consists of one ordinary share, par value $0.0001 per share, and one right entitling the holder thereof to receive one-eighth (1/8) of one ordinary share upon consummation of an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and rights are expected to be listed on NASDAQ under the symbols "WTG" and "WTGUR," respectively. Of the proceeds received from the consummation of the initial public offering (including the partial exercise of the over-allotment option) and a simultaneous private placement of 253,875 placement units to the Company's sponsor, MACRO DREAM Holdings Limited, for an aggregate purchase price of $2,538,750, a total of $56,089,875 (or $10.025 per public unit) was placed into a trust account in the United States at Wilmington Trust, National Association. The Company intends to use the net proceeds from the offering to acquire a business focused on the technology, media, and telecommunications industries. Its search for a target business will focus on companies with operations or prospective operations in the Asia Pacific region, including the Greater China region, that have advanced and highly differentiated solutions. D. Boral Capital LLC acted as sole book-running manager in the offering. Concord & Sage P.C. served as U.S. legal counsel to Wintergreen on the initial public offering, and Ogier served as Cayman Islands legal counsel to Wintergreen. Robinson & Cole LLP served as legal counsel to D. Boral Capital LLC. A registration statement on Form S-1 (File No. 333-286795) relating to these securities has been filed with the Securities and Exchange Commission ("SEC"), and was declared effective on May 28, 2025. The offering was made by means of a prospectus. Copies of the prospectus may be obtained from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, by phone at +1 (212) 970 5150 or emailing info@ Copies of the registration statement can also be obtained by visiting EDGAR on the SEC's website at No Offer This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Wintergreen Acquisition Corp. Wintergreen Acquisition Corp. is a newly incorporated blank check company incorporated as a Cayman Islands exempted company (company number 409590) for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Its search for a target business will focus on companies with operations or prospective operations in the Asia Pacific region, including the Greater China region, that have advanced and highly differentiated solutions. About D. Boral Capital D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America. A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately $30 billion in capital since its inception in 2020, executing ~350 transactions across a broad range of investment banking products. Forward-Looking Statement This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the prospectus and the Company's other filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. For more information, please contact: D. Boral Capital LLCEmail: info@ +1(212)-970-5150 SOURCE: D. Boral Capital LLC
Yahoo
30-05-2025
- Business
- Yahoo
Wintergreen Acquisition Corp. Announces the Closing of its Initial Public Offering and Partial Exercise of Underwriter's Over-Allotment Option to Purchase Additional Units
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Wintergreen Acquisition Corp. (NASDAQ: WTGUU) ('Wintergreen' or the 'Company') today announced the closing of its initial public offering of 5,595,000 units. This includes 595,000 units issued pursuant to the underwriter's partial exercise of its over-allotment option, which also closed today, May 30, 2025. The offering was priced at $10.00 per unit, resulting in gross proceeds of $55,950,000. Wintergreen's units are listed on the Nasdaq Capital Market ('NASDAQ') and began trading under the ticker symbol 'WTGUU' on May 29, 2025. Each unit consists of one ordinary share, par value $0.0001 per share, and one right entitling the holder thereof to receive one-eighth (1/8) of one ordinary share upon consummation of an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and rights are expected to be listed on NASDAQ under the symbols 'WTG' and 'WTGUR,' respectively. Of the proceeds received from the consummation of the initial public offering (including the partial exercise of the over-allotment option) and a simultaneous private placement of 253,875 placement units to the Company's sponsor, MACRO DREAM Holdings Limited, for an aggregate purchase price of $2,538,750, a total of $56,089,875 (or $10.025 per public unit) was placed into a trust account in the United States at Wilmington Trust, National Association. The Company intends to use the net proceeds from the offering to acquire a business focused on the technology, media, and telecommunications industries. Its search for a target business will focus on companies with operations or prospective operations in the Asia Pacific region, including the Greater China region, that have advanced and highly differentiated solutions. D. Boral Capital LLC acted as sole book-running manager in the offering. Concord & Sage P.C. served as U.S. legal counsel to Wintergreen on the initial public offering, and Ogier served as Cayman Islands legal counsel to Wintergreen. Robinson & Cole LLP served as legal counsel to D. Boral Capital LLC. A registration statement on Form S-1 (File No. 333-286795) relating to these securities has been filed with the Securities and Exchange Commission ('SEC'), and was declared effective on May 28, 2025. The offering was made by means of a prospectus. Copies of the prospectus may be obtained from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, by phone at +1 (212) 970 5150 or emailing info@ Copies of the registration statement can also be obtained by visiting EDGAR on the SEC's website at No Offer. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Wintergreen Acquisition Corp. Wintergreen Acquisition Corp. is a newly incorporated blank check company incorporated as a Cayman Islands exempted company (company number 409590) for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Its search for a target business will focus on companies with operations or prospective operations in the Asia Pacific region, including the Greater China region, that have advanced and highly differentiated solutions. Forward-Looking Statements This press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the prospectus and the Company's other filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. Source: Wintergreen Acquisition Corp. Contact: Wintergreen Acquisition YaoChief Executive Officer and ChairmanRoom 8326, Block B, Hongxiang Cultural and Creative Industrial Park,90 Jiukeshu West Road, Tongzhou District, Beijing, PRC Wintergreen Acquisition TanCFO008613652371477
Yahoo
25-03-2025
- Health
- Yahoo
Why the FDA is right about Zyn
The U.S. Food and Drug Administration recently authorized the marketing of 20 nicotine pouch products under the Zyn brand, including flavors like Wintergreen and the "unflavored" Chill. That authorization sparked a new round of proposed legislation, trend pieces and frustration. Meanwhile, the stock price for Philip Morris International Inc., which manufactures the smokeless product, has caught fire. Tobacco-control professionals fought long and hard for comprehensive legislation that would give FDA regulatory oversight over tobacco products and nicotine products that do not make therapeutic claims. But Zyn has proven to be especially controversial given a series of buzzy stories about its use by young people and its seeming popularity on social media sites like TikTok. So-called 'Zynfluencers' have led to fears that a new and youthful crowd could be looking to exploit the pouches for everything from long work days to clubbing. Most recently, Carrie Battan over at The New Yorker wrote about how Zyn pouches were becoming a 'staple for American dudes' in a dispatch announcing 'the new nicotine gold rush.' The good news is some of these fears may be overblown, especially fears about abuse by young people. The reality is that after being available on the U.S. market for 10 years, only 2.4% of U.S. high school students had used a nicotine pouch in the previous 30 days in 2024 (as compared to 7.8 % for electronic cigarettes). Zyn, like other new 'nicotine pouch' products, contains no tobacco. It consists of a pouch, a bit like a mini teabag, containing powdered nicotine, along with a few other ingredients such as noncaloric sweeteners and flavors. Each tin contains 15 pouches which are typically placed under the upper lip for up to an hour to allow the nicotine to be absorbed through the lining of the mouth. The amount of nicotine delivered by the 3 mg and 6 mg strength pouches is slightly higher than that delivered by 2 mg and 4 mg nicotine gum, but the peak is lower and slower than the nicotine delivered by a cigarette. In deciding whether to authorize these products, the FDA has to scrutinize a very detailed application and assess whether it is 'appropriate for the protection of public health' to allow the products to be sold on the U.S. market. This involves weighing the likely risks and benefits to the population, including youth, those not currently using any tobacco products and existing users. The 68-page summary of the FDA's January Zyn decision noted that the levels of 42 potentially harmful chemicals were so low in Zyn as to be undetectable. FDA officials concluded that the health risks from Zyn pouches are likely lower than potential risks from using snus (low toxicant smokeless tobacco) and the FDA has already concluded that some snus brands are significantly less harmful than cigarettes. In their summary decision statement, FDA also referred to data produced by the applicants from studies on the effects of Zyn on existing tobacco users. Officials mentioned that in one study, more than 60% of existing tobacco users reported using Zyn to help reduce or quit smoking. Another study found that nearly a quarter of existing tobacco users completely switched to Zyn. While the manufacturers of Zyn are not claiming that Zyn is a medicinal smoking cessation aid, the fact that relatively few young people are taking up Zyn use, whereas a meaningful proportion of smokers are likely to switch to the product, suggests that the benefits are likely to outweigh the risks. This, combined with the very low toxicant delivery profile of Zyn (particularly compared to cigarettes), convinced the FDA that it is appropriate for public health for Zyn products to be marketed in the U.S. This is the FDA doing its job exactly as required by the 2009 Tobacco Control Act. The real controversy about this decision should be in relation to the length of time it took. Over 2,000 brands of cigarettes are currently available on the U.S. market. Each one emits thousands of toxic chemicals, including carcinogens that are inhaled directly into the lungs, with consequences we are all too familiar with. It is a good thing that smokers now have legal access to a product that can deliver the same drug many are already addicted to (nicotine) but with far lower health risks than cigarettes. The day before announcing Zyn's marketing authorization, FDA Center for Tobacco Products announced another proposed rule that could have a massive impact on public health: a product standard that would limit the amount of nicotine permissible in cigarettes to nonaddictive levels. The timing may not have been coincidental. This 'low-nicotine cigarette' standard must pass through many steps before it can be implemented. One factor that may be key to its success is a wide selection of legal, less harmful (nonsmoked) nicotine products for nicotine-addicted smokers looking to switch. Zyn could be just such a product. So yes, it may seem like authorizing another nicotine product — especially one with its own youthful cultural cachet — is a risky decision. But when evaluating all the factors, it actually makes sense. This article was originally published on
